Priavoid GmbH | Clinical Trials Search

1,136 results for “Priavoid GmbH”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study

24 participants · First posted Aug 1, 2013

Bioequivalence Study of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)

30 participants · First posted May 11, 2023

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

24 participants · First posted Aug 5, 2016

A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.

28 participants · First posted Sep 30, 2016

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

26 participants · First posted Nov 23, 2021

Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions

24 participants · First posted Jan 10, 2024

Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed Condition

26 participants · First posted Jun 24, 2020

Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions

36 participants · First posted Jan 10, 2019

Influence of Non-invasive Neurostimulation (Transcutaneous Vagus Nerve Stimulation) on 1. the Noradrenergic Release in the Brain and 2. a Neuropsychological Memory Task

44 participants · First posted Apr 6, 2015

Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors

226 participants · First posted Jan 19, 2022

Page 1 of 7